<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72070">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01752842</url>
  </required_header>
  <id_info>
    <org_study_id>201112122</org_study_id>
    <secondary_id>P20HL113444-01</secondary_id>
    <nct_id>NCT01752842</nct_id>
  </id_info>
  <brief_title>Lipid Biomarkers for Diabetic Heart Disease</brief_title>
  <official_title>Lipid Biomarkers for Diabetic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leducq Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether lowering the delivery of excess fats to the heart in persons
      with type-2 diabetes mellitus improves heart muscle function. The investigators will also
      test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic
      heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening procedures include 12-hour fasting blood draw, urine pregnancy testing for
      females, completion of medical history questionnaire, and stress echocardiography to rule
      out coronary artery disease or cardiomyopathy.

      Subjects who meet screening criteria will return for visit 2, which consists of a urine
      collection, 12-hour fasting blood draw, dual-energy X-ray absorptiometry (DXA) for body
      composition, magnetic resonance spectroscopy analysis of the liver, and resting
      echocardiogram for analysis of heart structure and function. Subjects will then be
      randomized to treatment with fenofibrate (160 mg/d) or an identical-appearing placebo for 12
      weeks. They will be asked to continue their usual medications, diet and physical activity.
      Subjects will receive a pedometer to wear daily to track their physical activity. Subjects
      will meet with dietitians from the Lifestyle Intervention Core to complete a 24-hour dietary
      recall. They will be instructed to record their daily blood glucose concentrations, distance
      walked and any side effects, illnesses or stresses in a study-supplied log. Subjects will be
      instructed to either email or fax the log to the study coordinator each week (or discuss by
      phone).

      Subjects will return 6 weeks after starting intervention for visit 3 to ensure their medical
      safety. Procedures at this visit include an interim medical history, urine pregnancy test
      for females, blood draw to rule out untoward effects of the study drug on liver or kidney
      function, pill count to assess compliance, review of logs of blood glucose, distance walked,
      and side effects, illnesses or stresses, and meeting with a dietitian for a 24-hour dietary
      recall.

      Subjects will continue to take their study medication/placebo and keep logs of blood glucose
      levels, distance walked, and side effects, illnesses and stresses for another 6 weeks. They
      will return for visit 4 after 12 total weeks of intervention. Visit 4 involves a urine
      collection, 12-hour fasting blood draw, review of subject logs, pill count, and 24-hour
      dietary recall. In addition, magnetic resonance spectroscopy analysis of the liver and
      resting echocardiogram analysis of the heart will be performed to determine if there have
      been any changes in liver fat or heart function during the 12-week intervention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in cardiac function as measured by fractional shortening percent</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One fenofibrate 160 mg capsule per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for fenofibrate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One inert sugar pill per day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <arm_group_label>Fenofibrate</arm_group_label>
    <other_name>Tricor</other_name>
    <other_name>Triglide</other_name>
    <other_name>Antara</other_name>
    <other_name>Lipofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for fenofibrate</intervention_name>
    <arm_group_label>Placebo for fenofibrate</arm_group_label>
    <other_name>Sugar pill manufactured to mimic Fenofibrate 160 mg capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  triglycerides &gt; 150 mg/dL

        Exclusion Criteria:

          -  body weight &gt; 300 lb.

          -  HIV

          -  hypothyroid

          -  steroid medication, beta blocker, Ca++ channel blocker, fenofibrate

          -  smoking

          -  BP &gt; 140/90

          -  heart disease

          -  pregnant or lactating

          -  consumption of &gt; 5 alcoholic drinks/wk

          -  creatinine &gt; 1.5 mg/dL

          -  hematocrit &lt; 28
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean E Schaffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marsha S Farmer, MS</last_name>
    <phone>314-747-3357</phone>
    <email>mfarmer@dom.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha S Farmer, MS</last_name>
      <phone>314-747-3357</phone>
      <email>mfarmer@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Jean E Schaffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974 Jul;34(1):29-34. No abstract available.</citation>
    <PMID>4835750</PMID>
  </reference>
  <reference>
    <citation>Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy. JAMA. 1974 Sep 23;229(13):1749-54.</citation>
    <PMID>4278055</PMID>
  </reference>
  <reference>
    <citation>Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004 May 11;109(18):2191-6. Epub 2004 May 3.</citation>
    <PMID>15123530</PMID>
  </reference>
  <reference>
    <citation>Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, Gropler RJ. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol. 2006 Feb 7;47(3):598-604. Epub 2006 Jan 18.</citation>
    <PMID>16458143</PMID>
  </reference>
  <reference>
    <citation>Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, Unger R, Victor RG. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003 Mar;49(3):417-23.</citation>
    <PMID>12594743</PMID>
  </reference>
  <reference>
    <citation>Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 2004 Nov;18(14):1692-700.</citation>
    <PMID>15522914</PMID>
  </reference>
  <reference>
    <citation>Griffin JA, Osborn BW, Smithline HA. The impact of diabetes on hospital admissions, length of stay and mortality in emergency department patients with acute decompensated heart failure without ischemia. Acad Emerg Med. 2005;12:s97</citation>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>December 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Diabetic Cardiomyopathy</keyword>
  <keyword>Triglycerides</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
